Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data

OBJECTIVES: To investigate the cost-effectiveness of abatacept (ABA) as first-line (1L) therapy in Japanese rheumatoid arthritis (RA) patients using data from the Institute of Rheumatology, Rheumatoid Arthritis database. METHODS: A decision-analytic model was used to estimate the cost per American C...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Eiichi, Inoue, Eisuke, Shoji, Ayako, Nilsson, Jonas, Papagiannopoulos, Christos, Dhanda, Devender, Yoshizawa, Yuri, Abe, Mai, Saka, Kumiko, Sugano, Eri, Sugitani, Naohiro, Ochiai, Moeko, Yamaguchi, Rei, Ikari, Katsunori, Yamanaka, Hisashi, Harigai, Masayoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668164/
https://www.ncbi.nlm.nih.gov/pubmed/36383610
http://dx.doi.org/10.1371/journal.pone.0277566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668164/
https://www.ncbi.nlm.nih.gov/pubmed/36383610
http://dx.doi.org/10.1371/journal.pone.0277566

Ejemplares similares